Ultragenyx Reports Q3 Results, Plans 20% Workforce Reduction
Ultragenyx reported a third-quarter net loss of $118 million, narrowed from $180 million a year earlier, on revenue of $173 million. It reaffirmed 2026 revenue guidance of $730 million to $760 million, excluding new product launches, and said it entered agreements to sell two Priority Review Vouchers for $413 million combined, with expected net proceeds of about $350 million.
Ultragenyx Pharmaceutical Inc. reported a narrowed net loss of $118 million for the third quarter of 2026, compared to $180 million in the same period last year, on total revenue of $173 million. The company announced a strategic initiative to reduce its workforce by approximately 20% and lower future research and development and SG&A expenses to support its goal of achieving GAAP profitability in 2027. Additionally, the company reaffirmed its full-year 2026 revenue guidance of $730 million to $760 million, excluding new product launches.
Ultragenyx also disclosed that it entered into two definitive agreements in October 2026 to sell Priority Review Vouchers (PRVs) for a combined $413 million, with expected net proceeds of approximately $350 million.